Sebbesen Lars, Bilde Anders, Therkildsen Marianne, Mortensen Jann, Specht Lena, von Buchwald Christian
Department of Otorhinolaryngology, Head and Neck Surgery, and Audiology, Rigshospitalet and Faculty of Health and Medical Science, University of Copenhagen, Denmark.
Head Neck. 2014 Aug;36(8):1109-12. doi: 10.1002/hed.23414. Epub 2013 Oct 19.
Resection of the primary tumor followed by sentinel node biopsy (SNB) for the clinically N0 patient has been implemented in our Head and Neck University Center. The purpose of this study was to report on the outcome for patients with negative SNB.
From April 2007 to October 2009, 53 consecutive SNB-negative patients with oral cavity squamous cell carcinoma (SCC) T1 to T2 were accrued. Follow-up was done continuously with the most recent examination in October 2011. The location of the sentinel lymph nodes was determined using dynamic and planar lymphoscintigraphy and single photon emission CT (SPECT)-CT. Intraoperatively, a hand-held gamma probe was applied. The harvested sentinel lymph nodes underwent histopathologic examination using step-serial sectioning at 150-μm intervals and immunohistochemistry. In the follow-up period, we observed and examined the SNB-negative patients for recurrence, morbidity, and mortality.
Fifty-three SNB-negative patients were identified. Eight patients received adjuvant radiotherapy (RT) because of incomplete excision on the T site after the primary operation. An additional 2 patients received RT because of recurrences on the T site and N site. One patient died of recurrence on the T site and N site without having received additional treatment. Six patients died of nonrelated causes. During follow-up, 3 patients with both T-site and N-site recurrence were found. No case of isolated recurrence on the N site only was found. Thirty-six SNB-negative patients treated only surgically with a median follow-up of 37 months (range, 25-52 months) and no recurrence remain under active review.
Only 3 of the SNB-negative patients subsequently developed recurrence in the T site and N site. The remaining 36 patients had no N-site recurrence at median follow-up of 37 months.
在我们的头颈大学中心,对于临床N0患者,已实施原发性肿瘤切除术后进行前哨淋巴结活检(SNB)。本研究的目的是报告前哨淋巴结活检阴性患者的治疗结果。
从2007年4月至2009年10月,连续纳入53例前哨淋巴结活检阴性的口腔鳞状细胞癌(SCC)T1至T2患者。随访持续至2011年10月的最近一次检查。使用动态和平面淋巴闪烁显像及单光子发射计算机断层扫描(SPECT)-CT确定前哨淋巴结的位置。术中应用手持式γ探测器。对获取的前哨淋巴结进行间隔150μm的连续切片组织病理学检查及免疫组化。在随访期间,我们观察并检查前哨淋巴结活检阴性患者的复发、发病率和死亡率。
共确定53例前哨淋巴结活检阴性患者。8例患者因初次手术后T部位切除不完全而接受辅助放疗(RT)。另外2例患者因T部位和N部位复发而接受RT。1例患者未接受额外治疗死于T部位和N部位复发。6例患者死于非相关原因。随访期间,发现3例T部位和N部位均复发的患者。未发现仅N部位孤立复发的病例。36例仅接受手术治疗的前哨淋巴结活检阴性患者,中位随访37个月(范围25 - 52个月),目前仍在积极随访且无复发。
前哨淋巴结活检阴性的患者中,仅3例随后出现T部位和N部位复发。其余36例患者在中位随访37个月时无N部位复发。